BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 20088842)

  • 21. Treatment of iron overload in thalassemia.
    Cianciulli P
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Iron overload in sickle cell anemia : a study of 94 patients].
    Hafsia R; Belakhal F; Ben Salah N; Gouider E; Elborgi W
    Tunis Med; 2011 Jun; 89(6):548-52. PubMed ID: 21681718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
    Kikuchi S; Kobune M; Iyama S; Sato T; Murase K; Kawano Y; Takada K; Ono K; Kaneko Y; Miyanishi K; Sato Y; Hayashi T; Takimoto R; Kato J
    Free Radic Biol Med; 2012 Aug; 53(4):643-8. PubMed ID: 22705364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Consequences and management of iron overload in sickle cell disease.
    Porter J; Garbowski M
    Hematology Am Soc Hematol Educ Program; 2013; 2013():447-56. PubMed ID: 24319218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
    Remacha AF; Arrizabalaga B; Del CaƱizo C; Sanz G; Villegas A
    Ann Hematol; 2010 Feb; 89(2):147-54. PubMed ID: 19690857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome.
    OKABE H; SUZUKI T; OMORI T; MORI M; UEHARA E; HATANO K; UEDA M; MATSUYAMA T; TOSHIMA M; QZAKI K; NAGAI T; MUROI K; OZAWA K
    Rinsho Ketsueki; 2009 Nov; 50(11):1626-9. PubMed ID: 20009438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The deleterious effects of iron overload in patients with myelodysplastic syndromes.
    Dreyfus F
    Blood Rev; 2008 Dec; 22 Suppl 2():S29-34. PubMed ID: 19059054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The dangers of iron overload: bring in the iron police.
    Lambing A; Kachalsky E; Mueller ML
    J Am Acad Nurse Pract; 2012 Apr; 24(4):175-83. PubMed ID: 22486832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Iron overload: consequences, assessment, and monitoring.
    Taher AT; Musallam KM; Inati A
    Hemoglobin; 2009; 33 Suppl 1():S46-57. PubMed ID: 20001632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and economic burden of infused iron chelation therapy in the United States.
    Payne KA; Desrosiers MP; Caro JJ; Baladi JF; Lordan N; Proskorovsky I; Ishak K; Rofail D
    Transfusion; 2007 Oct; 47(10):1820-9. PubMed ID: 17880607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Iron overload in myelodysplastic syndromes: diagnosis and management.
    List AF
    Cancer Control; 2010 Jan; 17 Suppl():2-8. PubMed ID: 20125080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
    Leitch HA
    Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of iron overload in myelodysplastic syndromes.
    Fenaux P; Rose C
    Blood Rev; 2009 Dec; 23 Suppl 1():S15-9. PubMed ID: 20116635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality.
    Takatoku M; Uchiyama T; Okamoto S; Kanakura Y; Sawada K; Tomonaga M; Nakao S; Nakahata T; Harada M; Murate T; Ozawa K;
    Eur J Haematol; 2007 Jun; 78(6):487-94. PubMed ID: 17391310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective.
    Musallam KM; Cappellini MD; Wood JC; Taher AT
    Blood Rev; 2012 Apr; 26 Suppl 1():S16-9. PubMed ID: 22631036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iron-chelating therapy for transfusional iron overload.
    Musallam KM; Taher AT
    N Engl J Med; 2011 Apr; 364(15):1476; author reply 1477. PubMed ID: 21488787
    [No Abstract]   [Full Text] [Related]  

  • 37. Iron-chelating therapy for transfusional iron overload.
    Solomon LR
    N Engl J Med; 2011 Apr; 364(15):1475-6; author reply 1477. PubMed ID: 21488788
    [No Abstract]   [Full Text] [Related]  

  • 38. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concepts and goals in the management of transfusional iron overload.
    Porter JB
    Am J Hematol; 2007 Dec; 82(12 Suppl):1136-9. PubMed ID: 17968973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia.
    Porter JB; Davis BA
    Best Pract Res Clin Haematol; 2002 Jun; 15(2):329-68. PubMed ID: 12401311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.